⚠ R&D and Capacity Must Be Funded Through the CycleModerate threat

The technology moat is a compounding one only if the spending that feeds it never stops, and that creates a subtler vulnerability: ASML must fund enormous, long-horizon R&D and capacity investment through an industry cycle that is anything but steady. In a downturn, revenue can fall sharply while the research and the capacity build-out — committed years in advance, essential to staying ahead — cannot simply be switched off without ceding the lead. The company must spend as if the future is bright even when the present is not, a discipline that is easy to praise and hard to sustain.

ASML's monopoly economics and strong balance sheet make this affordable in a way few companies could match, and its long backlog smooths some of the cyclicality. But the tension is real: the moat widens only through spending that must continue across booms and busts, and a severe or prolonged downturn would test the company's willingness to keep pouring billions into research and capacity while revenue sagged. Cut back to protect near-term profit, and the lead narrows; spend through the trough, and profit suffers. Managing that trade-off — investing relentlessly in a cyclical business — is the permanent financial discipline the technology moat demands, and the compounding advantage is only as reliable as ASML's commitment to funding it when times are lean — a commitment €11 billion of 2025 free cash flow currently makes easy¹.